Skip to main content

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

Neuroscience and Behavioral Physiology volume 38, pages 639–645 (2008)Cite this article

Abstract

The efficacy of treatment with cerebrolysin was studied in 40 patients with cerebral vascular insufficiency. Cerebrolysin (20 daily i.v. infusions of 10 ml in 200 ml of physiological saline) was found to be an effective means of treating this group of patients. Courses of cerebrolysin treatment decreased the severity of memory and attention impairments, improving the overall cognitive status of the patients. Clinical observations and neuropsychological testing were supported by electrophysiological results, in terms of the P300 cognitive evoked potential. The effects of treatment at the doses used here were delayed and were seen three months after completion of treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. N. V. Vereshchagin and N. V. Lebedeva, “Mild forms of multi-infarct dementia: efficacy of cerebrolysin,” Sov. Med., 11, 6–8 (1991).

    PubMed  Google Scholar 

  2. B. S. Vilenskii, Stroke [in Russian], MIA, St. Petersburg (1995).

    Google Scholar 

  3. B. S. Vilenskii, G. M. Semenova, and E. A. Shirokov, “Use of cerebrolysin in ischemic stroke,” Zh. Nevrol. Psikhiat., 99, No. 4, 65–69 (1999).

    CAS  Google Scholar 

  4. M. Windisch, “Cerebrolysin — new results supporting multilateral actions,” in: Third International Symposium on Cerebrolysin [in Russian], Moscow (1991), pp. 81–106.

  5. V. V. Gnezditskii, Evoked Potentials in Clinical Practice [in Russian], Medpress-Inform, Moscow (2003).

    Google Scholar 

  6. E. I. Gusev and V. I. Skvortsova, Brain Ischemia [in Russian], Meditsina, Moscow (2001).

    Google Scholar 

  7. I. V. Damulin, “Use of cerebrolysin in vascular dementia and Alzheimer’s disease,” Ros. Med. Zh., 25, 1150–1156 (2002).

    Google Scholar 

  8. V. V. Zakharov and N. N. Yakhno, “Cognitive impairments in the aged and elderly,” in: Methods for Doctors [in Russian], Moscow (2005).

  9. V. V. Zakharov and I. V. Damulin, Diagnosis and Treatment of Impairments to Memory and Other Higher Brain Functions in the Elderly [in Russian], N. N. Yakhno (ed.), Moscow (1997).

  10. L. R. Zenkov and M. A. Ronkin, Functional Diagnosis of Nervous Diseases [in Russian], Medpress-Inform, Moscow (2004).

    Google Scholar 

  11. N. N. Koberskaya, Clinical and Electrophysiological Characteristics of Cognitive Impairments in Parkinson’s Disease and Symptomatic Parkinsonism [in Russian], Author’s Abstract of Master’s Thesis in Medical Sciences, Moscow (2003).

  12. N. N. Koberskaya, “The P300 cognitive potential,” Nevrol. Zh., 8, No. 6, 34–42 (2003).

    Google Scholar 

  13. N. K. Korsakova and L. I. Moskovichyute, Subcortical Brain Structures and Mental Processes [in Russian], Moscow State University, Moscow (1985).

    Google Scholar 

  14. A. B. Lokshina and V. V. Zakharov, “Mild and moderate cognitive disturbances in cerebral vascular insufficiency,” Nevrol. Zh., 11(Supplement 1), 57–64 (2006).

    Google Scholar 

  15. A. R. Luriya, Basic Neurology [in Russian], Academia, Moscow (2002).

    Google Scholar 

  16. V. A. Parfenov, A. A. Ryzhak, and Yu. A. Starchina, “Cognitive and emotional impairments in patients with arterial hypertension,” Nevrol. Zh., 11, (Supplement 1), 47–53 (2006).

    Google Scholar 

  17. E. I. Chukanova, “Effects of cerebrolysin on the progression and development of stroke in patients with cerebral vascular insufficiency,” Rus. Med. Zh., 14, No. 9, 652–657 (2006).

    Google Scholar 

  18. E. B. Shmidt, “Classification of vascular lesions of the brain,” Zh. Nevropatol. Psikhiat., 9, 1281–1288 (1985).

    Google Scholar 

  19. N. N. Yakhno, “Cognitive disorders in neurological practice,” Nevrol. Zh., 11(Supplement 1), 4–13 (2006).

    Google Scholar 

  20. N. N. Yakhno and I. V. Damulin, “Cerebral vascular insufficiency,” Ros. Med. Zh., 5, 3–7 (1999).

    Google Scholar 

  21. N. N. Yakhno, I. V. Damulin, V. V. Zakharov, et al., “Experience of the use of high doses of cerebrolysin in vascular dementia,” Ter. Arkh., 68, No. 10, 65–69 (1996).

    Google Scholar 

  22. N. N. Yakhno, O. S. Levin, and I. V. Damulin, “Comparison of clinical and MRI data in cerebral vascular insufficiency. 2. Cognitive impairments,” Nevrol. Zh., 6, No. 3, 10–18 (2001).

    Google Scholar 

  23. R. J. Boado, “In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides,” Eur. J. Neurol., 6, Supplement 3, 37 (1999).

    Google Scholar 

  24. S. Duma and N. Mutz, “Wirsamkeit einer Peptid-Dextran-Kombination in der Behandlung von Schadel-Hirn-Verletzten,” Neuropsychiatrie, 4, 69–72 (1990).

    Google Scholar 

  25. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “’Mini-mental state:’ a practical method for grading the cognitive state of patients for the clinician,” J. Psychiat. Res., 12, 189–198 (1975).

    PubMed  Article  CAS  Google Scholar 

  26. S. Gauthier, “Results of a 6-month randomized placebo-controlled study with Cerebrolysin in Alzheimer’s disease,” Eur. J. Neurol., 6, Supplement 3, 28 (1999).

    Google Scholar 

  27. D. S. Goodin and M. J. Aminoff, “Electrophysiological differences between demented and nondemented patients with Parkinson’s disease,” Ann. Neurol., 21, 90–94 (1987).

    PubMed  Article  CAS  Google Scholar 

  28. F. Jelasic, “Klinische Erfahrungen mit Cerebrolysin bei schweren hirnorganischen Prozessen,” 52, 1829–1831 (1976).

    CAS  Google Scholar 

  29. S. Koppi and G. S. Barolin, “Hamodilutionstherapie mit nervenzellstoffwechsel-aktiver Therapie beim ischamischen Insult: ermutigende Resultate einer Vergleichsstudie,” Wien Med. Wochschr., 146, No. 3, 41–48 (1996).

    CAS  Google Scholar 

  30. D. E. J. Linden, “The P300: Where in the brain is it produced and what does it tell us?” Neuroscientist, 11, 563–576 (2005).

    PubMed  Article  CAS  Google Scholar 

  31. S. Mattis, Dementia Rating Scale, Psychological Assessment Resources, Inc., Odessa (1988).

    Google Scholar 

  32. V. Monfort, V. Pathousa, and R. Ragot, “Role of frontal cortex in memory for duration: an event-related potential study in humans,” Neurosci. Lett., 286, 91–94 (2000).

    PubMed  Article  CAS  Google Scholar 

  33. R. C. Petersen, R. Doody, A. Kurz, et al., “Current concepts in mild cognitive impairment,” Arch. Neurol., 58, 1985–1992 (2001).

    PubMed  Article  CAS  Google Scholar 

  34. J. Polich, J. E. Alexander, and L. O. Bauer, “P300 topography of amplitude/latency correlations,” Brain Topogr., 9, 275–282 (1997).

    PubMed  Article  CAS  Google Scholar 

  35. J. Polich and A. Kok, “Cognitive and biological determinants of P300: an integrative review,” Biol. Psychol., 41, 103–146 (1995).

    PubMed  Article  CAS  Google Scholar 

  36. E. Ruther, H. Moessler, and M. Windisch, “The MAD-B Study: A randomized, double-blind, placebo-controlled trial with a Cerebrolysin in Alzheimer’s disease,” Neurobiol. Aging, 21, No. 1, 28 (2000).

    Article  Google Scholar 

  37. E. Ruther, R. Ritter, M. Apecechea, et al., “Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy,” J. Neural Transm., 107, 815–829 (2000).

    PubMed  Article  CAS  Google Scholar 

  38. H. Tashibana, K. Kawabata, M. Takeda, et al., “Multimodal evoked potentials in Binswanger’s disease and Alzheimer disease,” Int. J. Neurosci., 69, No. 1/4, 197–206 (1993).

    Article  Google Scholar 

  39. H. Tashibana, K. Toda, and M. Sugita, “Event-related potentials in patients with multiple lacunar infarcts,” Gerontology, 38, No. 6, 322–329 (1992).

    Article  Google Scholar 

  40. H. Tashibana, K. Toda, N. Yokota, et al., “Cerebral blood flow and event-related potential in patients with multiple cerebral infarcts,” Int. J. Neurosci., 60, No. 1/2, 113–118 (1991).

    Article  Google Scholar 

  41. M. Windisch, E. Albrecht, U. Eggenreich, and B. Paier, “Neurotrophic effects of the nootropic drug Cerebrolysin — a summary,” in: Third International Conference on Alzheimer’s Disease and Related Disorders, Padova (1992), pp. 4–5.

Download references

Author information

Affiliations

  1. Department of Nervous Diseases, I. M. Sechenov Moscow Medical Academy, Moscow, Russia

    I. V. Damulin, N. N. Koberskaya & É. A. Mkhitaryan

Authors
  1. I. V. Damulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. N. Koberskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. É. A. Mkhitaryan
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

__________

Translated from Zhurnal Nevrologii i Psikhatrii imeni S. S. Korsakova, Vol. 107, No. 5, pp. 32–38, May, 2007.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Damulin, I.V., Koberskaya, N.N. & Mkhitaryan, É.A. Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study). Neurosci Behav Physi 38, 639–645 (2008). https://doi.org/10.1007/s11055-008-9014-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-008-9014-5

Key words

  • cerebral vascular insufficiency
  • impairment of cognitive functions
  • cerebrolysin
  • 300 cognitive evoked potentials